These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 23157711)

  • 1. CNTO 530 increases expression of HbA and HbF in murine models of β-thalassemia and sickle cell anemia.
    Makropoulos DA; Achuthanandam R; Avery J; Wilson K; Brosnan K; Miller A; Nesspor T; Chroscinski D; Walker M; Egenolf D; Huang C; Bugelski PJ
    Curr Pharm Biotechnol; 2013; 14(2):242-8. PubMed ID: 23157711
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Augmentation by erythropoietin of the fetal-hemoglobin response to hydroxyurea in sickle cell disease.
    Rodgers GP; Dover GJ; Uyesaka N; Noguchi CT; Schechter AN; Nienhuis AW
    N Engl J Med; 1993 Jan; 328(2):73-80. PubMed ID: 7677965
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Monoterpenes as therapeutic candidates to induce fetal hemoglobin synthesis and up-regulation of gamma-globin gene: An in vitro and in vivo investigation.
    Iftikhar F; Khan MBN; Musharraf SG
    Eur J Pharmacol; 2021 Jan; 891():173700. PubMed ID: 33137331
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A short-term trial of butyrate to stimulate fetal-globin-gene expression in the beta-globin disorders.
    Perrine SP; Ginder GD; Faller DV; Dover GH; Ikuta T; Witkowska HE; Cai SP; Vichinsky EP; Olivieri NF
    N Engl J Med; 1993 Jan; 328(2):81-6. PubMed ID: 7677966
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reduction of the clinical severity of sickle cell/beta-thalassemia with hydroxyurea: the experience of a single center in Greece.
    Loukopoulos D; Voskaridou E; Kalotychou V; Schina M; Loutradi A; Theodoropoulos I
    Blood Cells Mol Dis; 2000 Oct; 26(5):453-66. PubMed ID: 11112383
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting fetal hemoglobin expression to treat β hemoglobinopathies.
    Steinberg MH
    Expert Opin Ther Targets; 2022 Apr; 26(4):347-359. PubMed ID: 35418266
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Induction of fetal hemoglobin synthesis with recombinant human erythropoietin in anemic patients with heterozygous beta-thalassemia during pregnancy.
    Breymann C; Fibach E; Visca E; Huettner C; Huch A; Huch R
    J Matern Fetal Med; 1999; 8(1):1-7. PubMed ID: 10052837
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Extended therapy with intravenous arginine butyrate in patients with beta-hemoglobinopathies.
    Sher GD; Ginder GD; Little J; Yang S; Dover GJ; Olivieri NF
    N Engl J Med; 1995 Jun; 332(24):1606-10. PubMed ID: 7753139
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combination therapy of erythropoietin, hydroxyurea, and clotrimazole in a beta thalassemic mouse: a model for human therapy.
    de Franceschi L; Rouyer-Fessard P; Alper SL; Jouault H; Brugnara C; Beuzard Y
    Blood; 1996 Feb; 87(3):1188-95. PubMed ID: 8562946
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reference values and hematologic changes from birth to 5 years in patients with sickle cell disease. Cooperative Study of Sickle Cell Disease.
    Brown AK; Sleeper LA; Miller ST; Pegelow CH; Gill FM; Waclawiw MA
    Arch Pediatr Adolesc Med; 1994 Aug; 148(8):796-804. PubMed ID: 7519102
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hydroxyurea therapy in thalassemia.
    Loukopoulos D; Voskaridou E; Stamoulakatou A; Papassotiriou Y; Kalotychou V; Loutradi A; Cozma G; Tsiarta H; Pavlides N
    Ann N Y Acad Sci; 1998 Jun; 850():120-8. PubMed ID: 9668534
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A recombinant human hemoglobin with anti-sickling properties greater than fetal hemoglobin.
    Levasseur DN; Ryan TM; Reilly MP; McCune SL; Asakura T; Townes TM
    J Biol Chem; 2004 Jun; 279(26):27518-24. PubMed ID: 15084588
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Oral sodium phenylbutyrate therapy in homozygous beta thalassemia: a clinical trial.
    Collins AF; Pearson HA; Giardina P; McDonagh KT; Brusilow SW; Dover GJ
    Blood; 1995 Jan; 85(1):43-9. PubMed ID: 7528572
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetics and pharmacodynamics of the erythropoietin Mimetibody construct CNTO 528 in healthy subjects.
    Pérez-Ruixo JJ; Krzyzanski W; Bouman-Thio E; Miller B; Jang H; Bai SA; Zhou H; Yohrling J; Cohen A; Burggraaf J; Franson K; Davis HM
    Clin Pharmacokinet; 2009; 48(9):601-13. PubMed ID: 19725594
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CNTO 530 functions as a potent EPO mimetic via unique sustained effects on bone marrow proerythroblast pools.
    Sathyanarayana P; Houde E; Marshall D; Volk A; Makropoulos D; Emerson C; Pradeep A; Bugelski PJ; Wojchowski DM
    Blood; 2009 May; 113(20):4955-62. PubMed ID: 19264917
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Differences in response to fetal hemoglobin induction therapy in beta-thalassemia and sickle cell disease.
    Fathallah H; Taher A; Bazarbachi A; Atweh GF
    Blood Cells Mol Dis; 2009; 43(1):58-62. PubMed ID: 19346141
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Improvement of erythropoiesis in beta-thalassemic mice by continuous erythropoietin delivery from muscle.
    Bohl D; Bosch A; Cardona A; Salvetti A; Heard JM
    Blood; 2000 May; 95(9):2793-8. PubMed ID: 10779423
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Oral administration of the LSD1 inhibitor ORY-3001 increases fetal hemoglobin in sickle cell mice and baboons.
    Rivers A; Vaitkus K; Jagadeeswaran R; Ruiz MA; Ibanez V; Ciceri F; Cavalcanti F; Molokie RE; Saunthararajah Y; Engel JD; DeSimone J; Lavelle D
    Exp Hematol; 2018 Nov; 67():60-64.e2. PubMed ID: 30125603
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacological induction of fetal hemoglobin in sickle cell disease and beta-thalassemia.
    Atweh GF; Loukopoulos D
    Semin Hematol; 2001 Oct; 38(4):367-73. PubMed ID: 11605172
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fetal globin stimulation during a short-term trial of erythropoietin in HbS/beta-thalassemia patients.
    Bourantas KL; Georgiou I; Seferiadis K
    Acta Haematol; 1994; 92(2):79-82. PubMed ID: 7529455
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.